| Company Name: | Alcon, Inc. | | Ticker Symbol: | ACL | | | WWW Address: | www.alcon.com |
| CEO: | Kevin J. Buehler | | No. of Employees: | 16,700 |
| Common Issue Type: | CS | | Business Description: | Alcon, Inc. develops, manufactures and markets pharmaceuticals, surgical equipment and devices and consumer eye care products to treat diseases and disorders of the eye.
|
| | | Industry Information: | HEALTH SERVICES - Medical Instruments & Supplies [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 167.99 |  0.0 | - | - | | 170.25 | 166.75 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 50,798.5 | 302.4 | 0.97 | 7.27 | 2.21 | 23.1 | 1.3 | 170.64 - 134.44 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 167.99 | $ | | PE Ratio - LTM | 23.1 | |
| Market Capitalisation | 50,798.5 | mil |
| Latest Shares Outstanding | 302.4 | mil |
| Earnings pS (EPS) | 7.27 | $ |
| Dividend pS (DPS) | 2.21 | ¢ |
| Dividend Yield | 1.3 | % |
| Dividend Payout Ratio | 30 | % |
| Revenue per Employee | 429,880 | $ |
| Effective Tax Rate | 12.5 | % |
| Float | 302.3 | mil |
| Float as % of Shares Outstanding | 100.0 | % |
| Foreign Sales | 4,002 | mil |
| Domestic Sales | 3,177 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 31.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 10.40 | % |
| Gross Profit Margin | 79.6 | % |
| EBITDA Margin | 38.3 | % |
| Pre-Tax Profit Margin | 35.2 | % |
| Assets Turnover | 0.8 | % |
| Return on Assets (ROA) | 21.9 | % |
| Return on Equity (ROE) | 30.5 | % |
| Return on Capital Invested (ROCI) | 30.5 | % |
| Current Ratio | 3.4 | |
| Leverage Ratio (Assets/Equity) | 1.4 | |
| Interest Cover | 281.8 | |
| Total Debt/Equity (Gearing Ratio) | 0.06 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 14.15 | $ |
| Cash pS | 8.35 | $ |
| Book-Value pS | 23.98 | $ |
| Tangible Book-Value pS | 18.08 | $ |
| Cash Flow pS | 8.21 | $ |
| Free Cash Flow pS | 1.20 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 7.00 | |
| Price/Tangible Book Ratio | 9.29 | |
| Price/Cash Flow | 20.5 | |
| Price/Free Cash Flow | 139.9 | |
| P/E as % of Industry Group | 116.0 | % |
| P/E as % of Sector Segment | 90.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | Cash Payment |
| Dividend Rate | 2.21 |
| Current Dividend Yield | 1.3 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 30.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.5 | 102 | 28,630 | 197,061 |
| 4 Weeks | 170.25 | 163.56 | 165.51 | 1.5 | 100 | 34,318 | 686,364 |
| 13 Weeks | 170.25 | 162.25 | 162.87 | 3.1 | 99 | 20,101 | 1,266,388 |
| 26 Weeks | 170.64 | 157.21 | 166.68 | 0.8 | 88 | 16,052 | 2,022,583 |
| 52 Weeks | 170.64 | 134.44 | 160.28 | 4.8 | 94 | 12,672 | 3,205,914 |
| YTD | 170.25 | 162.25 | - | 2.8 | 97 | 19,441 | 1,321,975 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 167.25 | 166.45 | 165.17 | 164.69 | 162.54 | 0.97 | 1.04 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 10.36 | 97.5 | 8.09 |
| Income | 18.63 | 87.8 | 10.05 |
| Dividend | 23.96 | 71.4 | 20.54 |
| Capital Spending | 38.63 | NA | 42.20 |
| R&D | 11.26 | NA | 9.57 |
| Normalized Inc. | 18.38 | NA | 9.72 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 10.5 | 5.7 | 10.5 |
| Earnings % | 10.1 | 13.8 | 10.1 |
| EPS % | 9.2 | 13.2 | 9.2 |
| EPS $ | 0.61 | 0.20 | 0.61 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 42.47 |
| Current Ratio | 3.4 |
| Quick Ratio (Acid Test) | 2.7 |
| Liquidity Ratio (Cash) | 1.91 |
| Receivables Turnover | 5.1 |
| Average Collection Period | 71 |
| Working Capital/Equity | 59.0 |
| Working Capital pS | 14.15 |
| Cash-Flow pS | 8.21 |
| Free Cash-Flow pS | 1.20 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 13.30 |
| Financial Leverage Ratio (Assets/Equity) | 1.4 |
| Debt Ratio | 28.0 |
| Total Debt/Equity (Gearing Ratio) | 0.06 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 14.2 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 281.8 |
| Interest/Capital Invested | 0.11 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 7.90 |
| Tobin's Q Ratio | 5.04 |
| Current P/E Ratio - LTM | 23.10 |
| Enterprise Value (EV)/EBITDA | 18.28 |
| Enterprise Value (EV)/Free Cash Flow | 150.31 |
| Dividend Yield | 1.3 |
| Price/Tangible Book Ratio - LTM | 9.29 |
| Price/Book Ratio - LTM | 7.00 |
| Price/Cash Flow Ratio | 20.5 |
| Price/Free Cash Flow Ratio - LTM | 139.9 |
| Price/Sales Ratio | 7.08 |
| P/E Ratio (1 month ago) - LTM | 22.7 |
| P/E Ratio (26 weeks ago) - LTM | 22.8 |
| P/E Ratio (52 weeks ago) - LTM | 24.1 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 116.0 |
| P/E as % of Sector Segment | 90.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 23.1 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 5.92 |
| Tangible Book Value pS - LTM | 18.08 |
| Book Value pS - LTM | 23.98 |
| Capital Invested pS | 23.98 |
| Cash pS - LTM | 8.35 |
| Cash Flow pS - LTM | 8.21 |
| Free Cash Flow pS - LTM | 1.20 |
| Earnings pS (EPS) | 7.27 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 5.06 |
| Free Cash Flow Margin 5YEAR AVG | 11.62 |
| Net Profit Margin | 30.8 |
| Net Profit Margin - 5YEAR AVRG. | 30.2 |
| Equity Productivity | 0.99 |
| Return on Equity (ROE) | 30.5 |
| Return on Equity (ROE) - 5YEAR AVRG. | 38.1 |
| Capital Invested Productivity | 0.99 |
| Return on Capital Invested (ROCI) | 30.5 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 37.8 |
| Assets Productivity | 0.80 |
| Return on Assets (ROA) | 21.9 |
| Return on Assets (ROA) - 5YEAR AVRG. | 23.7 |
| Gross Profit Margin | 79.6 |
| Gross Profit Margin - 5YEAR AVRG. | 78.7 |
| EBITDA Margin - LTM | 38.3 |
| EBIT Margin - LTM | 35.3 |
| Pre-Tax Profit Margin | 35.2 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 34.4 |
| Effective Tax Rate | 12.5 |
| Effective Tax Rate - 5YEAR AVRG. | 12.4 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 237 |
| Revenue per Employee | 429,880 |
| Net Income per Employee | 132,335 |
| Average Collection Period | 75 |
| Receivables Turnover | 5.1 |
| Day's Inventory Turnover Ratio | 162 |
| Inventory Turnover | 2.2 |
| Inventory/Sales | 9.7 |
| Accounts Payble/Sales | 5.15 |
| Assets/Revenue | 1.25 |
| Net Working Capital Turnover | 1.68 |
| Fixed Assets Turnover | 1.79 |
| Total Assets Turnover | 0.8 |
| Revenue per $ Cash | 2.84 |
| Revenue per $ Plant | 5.17 |
| Revenue per $ Common Equity | 0.99 |
| Revenue per $ Capital Invested | 0.99 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 31.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 30.2 |
| Research & Devlopment (R&D) as % of Revenue | 10.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 10.4 |
|
|  
| | |  |  | |
| |
